Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
about
The detection, treatment, and biology of epithelial ovarian cancerIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancerOptimal primary surgical treatment for advanced epithelial ovarian cancerIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancerMajor clinical research advances in gynecologic cancer in 2013The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialMyosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motilityChinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignanciesEvolution of management in peritoneal surface malignanciesManagement of relapsed ovarian cancer: a reviewTreatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectivesCytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and futureRepeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomesChemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapyChemotherapy of ovarian cancer in elderly patientsAbdominal metastases from colorectal cancer: intraperitoneal therapyBreakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanesCytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live SurgeryHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerHow to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts?Ports and complications for intraperitoneal chemotherapy deliveryTargeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewLooking up: Recent advances in understanding and treating peritoneal carcinomatosisOvarian cancer standard of care: are there real alternatives?Profile of pazopanib and its potential in the treatment of epithelial ovarian cancerUpper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatmentClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerGastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively?Current status and evolution of preclinical drug development models of epithelial ovarian cancerPatient preferences in advanced or recurrent ovarian cancer.Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Advanced ovarian cancer: what should be the standard of care?The role of surgery in advanced epithelial ovarian cancerNew perspectives on targeted therapy in ovarian cancerA systematic review of ovarian cancer and fear of recurrenceThe evolving role of catumaxomab in gastric cancerA genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpressionFunctional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylationA phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
P2860
Q21198791-D1CE0DD2-BE0E-4C24-A4A5-7B5320788803Q24186509-1A64A7DF-1825-4648-9E45-9F263AF71299Q24234923-35D780C1-3457-4C6B-A345-5716106627D1Q24235235-47A162A9-E961-4247-8E02-3FA477BE994FQ24562146-68426841-32F2-4400-8AEA-1F7BE86A1406Q24629295-97D8709A-AE35-470B-BF57-8734243E5AEEQ24672758-65544A83-9B57-40A3-AACD-3D0BDE6AE030Q26738517-2ADB945F-B158-4EFA-9091-9025119CACE8Q26741293-CD905704-80F7-452E-9BEC-90835E1705DCQ26741755-4CE838FA-AA20-4F59-AD76-10D1296C046CQ26744031-7DC73500-8B94-49F3-890A-AB174FE3C379Q26768296-1993DF05-05C7-492C-9CDF-AC7E3AB5F9FCQ26768299-FC37D224-7080-4A80-8FFD-EABF50E1AC1CQ26768402-FF1C1890-E652-4285-913F-9866CE5BFD2FQ26771397-C2D06908-FD38-419D-8BC0-CE080976B41EQ26772268-DF0BC445-2D19-4BFB-9C47-83CE72A30A36Q26776201-650FB6E9-57B7-4F51-B5AB-D46E30BED008Q26780342-A0CF4376-CCAE-49B3-9E97-20071125CD58Q26783551-83FD0A08-D132-48DD-86AA-201F95F3EEC7Q26796520-4807F220-69A5-42ED-AD2F-39F02BA1882BQ26822458-A53BA966-7123-4A37-89F0-F5F04EA982A9Q26828581-0652D21E-7EFF-45A6-988E-C9F39E6ADAE6Q26849259-238C0842-79CD-4B3D-8C21-51C99D510138Q26862249-A4BFC845-1CB7-4B4A-B8A8-C1A999DF9A86Q27011840-FB18DE44-BD79-4EB0-92F3-69F3B3EC5D01Q27021915-84E018CB-CE8E-494D-ACD2-7DA8896E4406Q27024235-96D99DB3-F20B-4A36-960C-B1955463622BQ27026303-6C1DD002-83CA-48D6-AAAD-8C0D6F82F9FEQ27028117-A515CB26-C792-48F6-B35C-8755B690DD83Q27336251-0C285424-7F53-421F-888E-712548A5A53DQ27687617-C4AB64B7-8434-4B78-93D7-9247E2CE789CQ27851688-419F4A3E-DC9B-4278-A61E-CE36A3189FF8Q27852053-EA3E054B-0609-4574-80BE-6C6164D1E8EBQ28067698-A97451D3-64EE-40E2-A2AD-EFD68E130C7CQ28082524-D974E845-119C-4A8E-B1CC-57828FC30663Q28087206-1D63E7B7-56EF-4BBC-B104-377AA34467FAQ28290511-FED46F94-BBF4-4386-ABAB-2DDB43018F0EQ28611264-AD66C7C9-9055-42EC-96BB-F7F0ECB01A7DQ29248201-211CCF0F-5D05-4B64-94D3-46522EA43371Q30252871-AAEAB144-8329-4902-BB43-933B6305A9AE
P2860
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@en
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@nl
type
label
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@en
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@nl
prefLabel
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@en
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@nl
P2093
P356
P1476
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
@en
P2093
Brian Bundy
Deborah K Armstrong
Gynecologic Oncology Group
Helen Q Huang
Joan L Walker
Lari Wenzel
Larry J Copeland
Rebecca Baergen
Robert A Burger
Shashikant Lele
P356
10.1056/NEJMOA052985
P407
P577
2006-01-01T00:00:00Z